Background: Neonatal diabetes mellitus (NDM) caused by mutations in KCNJ11 can be successfully treated with high dose oral sulfonylureas; however, little data is available on the risk of hypoglycemia.
| INTRODUCTION
Persistent hyperglycemia requiring treatment diagnosed within the first 6 months of life is referred to as neonatal diabetes mellitus (NDM). NDM is a rare condition with an estimated incidence of 1 in 90 000 to 160 000 live births.
1,2 NDM may be transient or permanent and is typically monogenic in etiology with over 20 genes implicated 3 . Mutations in KCNJ11, one of the genes encoding the ATPsensitive potassium (K ATP ) channel, represent the most common cause of permanent NDM and are frequently associated with developmental delay and neurological features. 4, 5 The identification of KCNJ11 mutations has dramatic clinical implications with the majority of patients being able to transition from insulin therapy to oral sulfonylurea (SU) treatment. 4 A number of reports have demonstrated measurable improvements in neurodevelopmental capabilities after transitioning to SU treatment in KCNJ11-related diabetes [6] [7] [8] [9] and some limited data suggests earlier introduction of SUs is advantageous. 10 However, there is limited data on hypoglycemia in NDM subjects treated with SU medications. We sought to determine the frequency, severity, and clinical significance of hypoglycemia in subjects with KCNJ11-related diabetes in order to evaluate the risks and benefits of adjusting SU treatment in this group.
| RESEARCH DESIGN AND METHODS
All subjects were consented for participation through protocols This tool queried frequency and severity of hypoglycemia since starting SU treatment, frequency of home glucometer measurements, self-defined hypoglycemia threshold, symptoms associated with hypoglycemia, and other medication side effects ( Figure S1 , Supporting information). Caregivers were asked about the frequency of hypoglycemia that they deemed 'mild to moderate' (defined in our survey as "conscious and mostly able to help themselves") and episodes of hypoglycemia that they deemed "severe" (defined in our survey as "partially or fully unconscious, having a seizure, or otherwise unable to assist with their own care" following published guidelines from ISPAD (2009) and ADA (2005)). 12, 13 All episodes of hypoglycemia that were deemed "severe" by caregivers were reviewed in detail by our research team according to current ISPAD guidelines (2014) that define "severe" as involving seizures or loss of consciousness. 14 This questionnaire was delivered online using REDCap and was sent in conjunction with another study on behavior and sleep characteristics of this population. 15 Inclusion criteria for our study were those patients in the University of Chicago Monogenic Diabetes Registry identified to have a mutation in KCNJ11 as the cause of their diabetes who are currently taking SU therapy and whose caregivers responded to follow-up contact for this study. Data are displayed as median (interquartile range, IQR) unless otherwise specified. All data collected were self-reported by the subject or caregiver. and proband responders (n = 28) and non-responders (n = 24) were similar by all characteristics, including household income and age at assessment, as reported previously. 15 The majority of responses were from parents or guardian caregivers who completed the questionnaire on behalf of subjects, who were mostly children (mean age:
years, median: 8 years [5.25-12.75 IQR]). The specific KCNJ11
variants included R201H (n = 10), R201C (n = 5), V59 M (n = 7) and other less common variants (one each of G53D, H46L, I182T, Q52L, and V59A, and two with H186D). 4 The median age at diagnosis was 0.15 years (0.09-0.29 IQR), the median age at SU initiation was who reported hypoglycemia as "once a week" or "more than once a week" had SU doses of 2.354, 0.405 and 0.386 mg/kg/day (Table 2) .
Six respondents (n = 28; 21.4%) reported at least one episode of hypoglycemia they deemed "severe" since starting SU treatment (survey definition: "partially or fully unconscious, having a seizure, or otherwise unable to assist with their own care"). However, upon expert review, none of these events were clinically severe based on the 2014 ISPAD definition of severe hypoglycemia in children (seizure or loss of consciousness). Further information on these 6 episodes, as well as SU doses and HbA1c comparisons for these subjects, can be found in Table S1 .
When respondents were asked what they considered to be a 
| DISCUSSION
SU use has transformed the lives of NDM subjects with mutations associated with the K ATP channel. 4, 16 In other forms of diabetes, 20, 21 No one in our cohort had any hypoglycemic episodes consistent with the current ISPAD definition of severe hypoglycemia in children-seizures or full unconsciousness due to hypoglycemia.
Reported rates of severe hypoglycemia in pediatric and adolescent subjects with type 1 diabetes taking insulin vary from 8 to 30 events per 100 patient-years. 12 In a recent meta-analysis of patients with type 2 diabetes taking SUs, the incidence of severe hypoglycemia was reported at 0.8% (studies analyzed ranged from 0 to 0.1 episodes of severe hypoglycemia per patient per year), equivalent to 0 to 10 events per 100 patient-years. 22 While we cannot rule out the possibility that some episodes of severe hypoglycemia may have been undetected or unreported within our cohort, given that the responders were similar to the non-responders, we believe this reporting an average of 91 min/day (6% of time) <70 mg/dL. 23, 24 It is important to note that both of these studies were randomized controlled trials, so may have attracted more motivated or more closely controlled patients. Interestingly, there are also studies of CGM use in various non-diabetes populations, including 32 adult subjects with normal glycemic tolerance that spent 3.2% AE 3% of the time with CGM <70 mg/dL, with a range of 0% to 12%, 25 while another study of 74 healthy controls showed some age-dependence in spending 0.6% to 2.9% of the time with CGM <70 mg/dL (the youngest group was 8-15 years of age and was similar to the overall average at 1.8% of the time). 26 Our data suggests that mild to moderate hypoglycemia occurs in those with KCNJ11-related diabetes, but within our cohort, was not severe according to current ISPAD definitions. Because the participants were not checking their glucose levels very frequently (40% of subjects checked their blood glucose once a week or less often),
there is uncertainty about how often mild to moderate hypoglycemia is occurring in this group of subjects; future study will be required to clarify the true frequency. Of note, the frequency of mild to moderate hypoglycemia is rarely and inconsistently reported in the type 1 diabetes literature since it occurs so frequently. 
| Limitations
This study began prior to 2014, and thus, now outdated definition of severe hypoglycemia was used on survey materials. By reviewing all episodes using the current 2014 ISPAD guidelines, we were able to clarify that none of these episodes were clinically severe. Although these episodes did not involve seizures or unconsciousness, the fact that they involved hypoglycemia and were concerning to caregivers supports the need for additional research on the determinants of hypoglycemia in this study population, whether or not it is severe.
Their survey used in this study has not been validated previously, although it was created through a multistep process, as described in Section 2. Most information collected in this study was based on caregiver report, and thus may be more susceptible to recall bias than data derived from blood glucose monitoring devices or medical records.
| Summary
Of all reported episodes of hypoglycemia, none were severe according to the current ISPAD definition. There was a wide range of SU doses and hypoglycemia frequency reported, indicating higher doses do not correlate with hypoglycemia in this cohort. Further study will be necessary to clarify what the optimal target HbA1c value should be in this population. We also demonstrate the wide variability in the frequency of glucometer testing and self-defined hypoglycemia in those with KCNJ11-related NDM. It is most useful to focus on the data from blood glucose readings and CGM, and to continue to inquire about hypoglycemia with these patients and caregivers. More research is needed in order to better estimate hypoglycemic frequency in this population, determine the causes of these hypoglycemic episodes, and determine whether it is the SU dose or outside factors that play a larger role. These studies might include investigations into insulin secretion or counter-regulatory responses in patients with K ATP channel mutations.
